——–
“Click Therapeutics, Inc. (“Click”), a company developing a suite of personalized data-driven digital therapeutics for chronic health conditions, announces today preliminary results of its fully remote clinical trial of Clickotine, a digital program designed for smoking cessation.
The study was conducted to investigate the feasibility of a fully digital clinical trial, to validate the engagement of the CLICK Neurobehavioral Intervention (CNI) Platform, and to explore the efficacy of Clickotine for smoking cessation…In a digital, 8-week, IRB-approved open-label clinical trial, Clickotine was provided to 416 participants who enrolled in the trial over the 9-week period of recruitment…According to Nicholas Schork, Ph.D., the Principal Investigator of the Clickotine trial and also a Professor at the J. Craig Venter Institute as well as the Translational Genomics Research Institute: “This study demonstrates the potential of conducting a trial of a therapeutic intervention digitally. The user engagement, data integrity, and efficiency provided by the Click platform were exceptional”…Click is planning a large-scale randomized controlled clinical trial to confirm these results.
To learn more:
- Meet Dr. Brian Iacoviello, Director of Scientific Affairs at Click Therapeutics, at the upcoming 2016 SharpBrains Virtual Summit (December 6-8th)